Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shu Nao Xin Dripping Pill (also known as Shunaoxin Dripping Pill or Shu Nao Xin Di Wan) is a traditional Chinese medicine (TCM) developed and manufactured by Tianjin Pharmaceutical Da Ren Tang Group (formerly Tianjin Zhongxin Pharmaceutical Group). It is formulated as a solid dispersion dripping pill containing extracts from two primary herbal ingredients: *Ligusticum chuanxiong* (Chuanxiong) and *Angelica sinensis* (Danggui). The preparation is clinically approved in China (since 2005) for the treatment of cerebrovascular and cardiovascular diseases, particularly migraine, dizziness, blurred vision, amnesia, and insomnia caused by blood deficiency and blood stasis. Pharmacologically, Shu Nao Xin Dripping Pill regulates qi, promotes blood circulation, removes blood stasis, and exerts neuroprotective and anti-platelet aggregation effects. It has been shown to dilate cerebral blood vessels, increase cerebral blood flow, and inhibit ferroptosis, potentially through the activation of the AKT/Nrf2/HO-1 signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shu Nao Xin Dripping Pill.